Aratana Theraptcs Cmn (PETX) 8.81 $PETX Technical

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aratana Theraptcs Cmn (PETX) 8.81 $PETX

Technical Roundup on Biotech Stocks -- Anavex Life Sciences, Threshold Pharma, StemCells, and Aratana Therapeutics
PR Newswire - Wed Aug 17, 7:17AM CDT
Biotechnology is a risk-taking arena where investors either come out a winner or the other way around. The industry is involved in drug development and clinical researches that are intended to treat and cure various medical conditions. Stock-Callers.com takes a look at these equities and see how they performed at the closing bell on Tuesday, August 16, 2016: Anavex Life Sciences Corp. (NASDAQ: AVXL), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), StemCells Inc. (NASDAQ: STEM), and Aratana Therapeutics Inc. (NASDAQ: PETX). Access these companies' trade alerts for free by signing up now at: Sign up today and download for free the research reports for the stocks covered today at: http://stock-callers.com/registration
AVXL: 3.05 (+0.02), STEM: 1.54 (unch), PETX: 8.81 (-0.11), THLD: 1.21 (+0.16)

Aratana Therapeutics Granted FDA Approval of NOCITA® (bupivacaine liposome injectable suspension)
PR Newswire - Mon Aug 15, 3:30PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) approved NOCITA® (bupivacaine liposome injectable suspension) as a local post-operative analgesia for cranial cruciate ligament surgery in dogs. Aratana anticipates Nocita will be commercially available to veterinarians in the fall of 2016.
PETX: 8.81 (-0.11)

Aratana Therapeutics (PETX) Worth a Look: Stock Gains 6.2%
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 7:45AM CDT
Aratana Therapeutics, Inc. (PETX) was a big mover last session, as the company saw its shares rise over 6% on the day.
AKAO: 4.25 (+0.26), PETX: 8.81 (-0.11)

The Zacks Analyst Blog Highlights: Aratana Therapeutics, Dynavax Technologies, Heron Therapeutics and La Jolla Pharmaceutical
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:30AM CDT
The Zacks Analyst Blog Highlights: Aratana Therapeutics, Dynavax Technologies, Heron Therapeutics and La Jolla Pharmaceutical
DVAX: 10.91 (-5.03), HRTX: 17.70 (-0.63), LJPC: 16.15 (-0.33), PETX: 8.81 (-0.11)

Aratana Therapeutics Reports Second Quarter 2016 Financial Results
PR Newswire - Thu Aug 04, 3:20PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced its second quarter 2016 financial and operational results. For the quarter ended June 30, 2016, Aratana reported net income of $21.2 million or $0.61 diluted net income per share, which includes $38 million in revenue from the collaboration, license, development and commercialization agreement with Elanco Animal Health, a division of Eli Lilly and Company.
PETX: 8.81 (-0.11), LLY: 76.85 (-0.38)

Drug Stocks' Earnings to Watch on Aug 5: PETX, DVAX & More
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 9:33AM CDT
What's in store for drug stocks Dynavax, Aratana and others when they report their Q2 results on Aug 5?
DVAX: 10.91 (-5.03), JNJ: 119.32 (+0.24), HRTX: 17.70 (-0.63), GILD: 76.89 (-0.53), LJPC: 16.15 (-0.33), PETX: 8.81 (-0.11)

First Week of February 2017 Options Trading For Aratana Therapeutics
StockOptionsChannel.com - Tue Jun 28, 9:33AM CDT
Investors in Aratana Therapeutics, Inc saw new options begin trading this week, for the February 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration...
PETX: 8.81 (-0.11)

Aratana Therapeutics Receives CMC Technical Section Complete Letter for Post-Operative Pain Therapeutic
PR Newswire - Thu Jun 02, 8:23AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced today that the Company received a technical section complete letter for chemistry, manufacturing and controls (CMC) for NOCITA® (bupivacaine liposome injectable suspension) from the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM). Nocita is being investigated as a therapeutic option to provide local post-operative analgesia for cranial cruciate ligament surgery in dogs and works as a long-acting local anesthetic designed to provide up to 72 hours of post-operative pain control.
PETX: 8.81 (-0.11)

Aratana Therapeutics to Participate at Two Upcoming Investor Conferences
PR Newswire - Mon May 23, 7:30AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, plans to present at Stifel Dental & Veterinary Conference on Wednesday, June 1 at 10:55 a.m. ET in New York City and at Jefferies Healthcare Conference on Tuesday, June 7 at 2:30 p.m. ET in New York City.
PETX: 8.81 (-0.11)

Aratana Therapeutics Granted FDA Approval of ENTYCE® (capromorelin oral solution)
PR Newswire - Tue May 17, 4:46PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) approved Entyce for appetite stimulation in dogs. Aratana intends to commercially launch Entyce in conjunction with the North American Veterinary Conference in February 2017.
PETX: 8.81 (-0.11)

Aratana reports 1Q loss
Automated Insights - Thu May 05, 5:38PM CDT
LEAWOOD, Kan. (AP) _ Aratana Therapeutics Inc. (PETX) on Thursday reported a loss of $18.1 million in its first quarter.
PETX: 8.81 (-0.11)

Aratana Therapeutics Reports First Quarter 2016 Financial Results
PR Newswire - Thu May 05, 3:05PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative pharmaceutical products for companion animals, announced its first quarter 2016 financial and operational results. For the quarter ended March 31, 2016, Aratana reported a net loss of $18.1 million or $0.52 basic loss per share.
PETX: 8.81 (-0.11), LLY: 76.85 (-0.38)

Aratana Therapeutics to Present at Bank of America Merrill Lynch Healthcare Conference
PR Newswire - Mon May 02, 8:00AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on May 10, 2016 at 5:00 p.m. PT.
PETX: 8.81 (-0.11)

Aratana Therapeutics to Discuss Global Strategic Collaboration with Elanco Animal Health
PR Newswire - Mon Apr 25, 3:10PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals will host a conference call today, Monday, April 25, 2016, at 6:00 p.m. ET to update the investment community regarding the strategic collaboration with Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) that was announced this afternoon.
PETX: 8.81 (-0.11), LLY: 76.85 (-0.38)

Aratana, Elanco Announce Global Strategic Collaboration
PR Newswire - Mon Apr 25, 3:05PM CDT
Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced that Elanco has licensed animal health rights to Aratana's Galliprant (grapiprant tablets), an FDA-approved therapeutic for the control of pain and inflammation associated with osteoarthritis in dogs. The agreement grants Elanco exclusive rights to develop, manufacture, market, and commercialize Galliprant globally, and co-promote the product with Aratana in the United States.
PETX: 8.81 (-0.11), LLY: 76.85 (-0.38)

Why Patents are the Lifeblood of Biotech Companies
ACCESSWIRE - Mon Apr 25, 8:36AM CDT
Protection of Intellectual Property Is At the Core of the Business for Biotechnology Firms
RPTP: 7.28 (+0.04), EBIO: 4.84 (-0.05), PTCT: 7.91 (+0.12), PETX: 8.81 (-0.11), ARRY: 3.50 (-0.02)

Aratana Therapeutics to Report First Quarter 2016 Financial Results
PR Newswire - Thu Apr 14, 3:05PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, will host a live conference call on Friday, May 6, 2016 at 8:30 a.m. ET to discuss financial results for the first quarter ending March 31, 2016.
PETX: 8.81 (-0.11)

Biotech Volatility Both Good And Bad
ACCESSWIRE - Thu Apr 07, 8:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 7, 2016 / Jim Cramer made a great point about investing in biotech's that I think is worth addressing. After the decline in the biotech industry last week, he announced he was a buyer. But, that's not the major point. He continued, expressing that there is huge risk involved in any biotech, but with that risk comes the opportunity for tremendous rewards.
CERU: 1.02 (unch), VVUS: 1.05 (-0.01), PETX: 8.81 (-0.11), GALE: 0.40 (unch)

Aratana Therapeutics to Present GALLIPRANT® (grapiprant tablets) Pivotal Data
PR Newswire - Thu Mar 31, 8:00AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the Company plans to showcase Galliprant pivotal efficacy and safety data at the American Animal Hospital Association (AAHA) annual conference in Austin, Texas on Saturday, April 2, 2016 from 7:00 - 7:50 a.m. Lesley Rausch-Derra, DVM, MS, Vice President of Regulatory Affairs and Drug Development at Aratana Therapeutics, will present the pivotal data during the Sunrise Session for registered conference attendees. Presentation slides are also available in the Aratana Investor Room.
PETX: 8.81 (-0.11)

ChemoCentryx (CCXI) Rises: Stock Adds 8.2% in Session
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 7:45AM CST
ChemoCentryx, Inc. (CCXI) was a big mover last session, as the company saw its shares rise over 8% on the day.
CCXI: 4.22 (-1.07), PETX: 8.81 (-0.11)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 76

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 69

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 106

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
SoCalGas Data Program Puts Metering Case Into Focus

Updated Category News Views 61

Buried beneath the usual utility-company polish is a pretty sensible idea: find waste before a customer gets walloped by a bill. SoCalGas says its Advanced Meter Analytics program has helped customers avoid an estimated $11 million in unnecessary natural-gas costs since 2019. That is not a number likely to move Sempra’s earnings by itself, and nobody should pretend...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 50

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading
GreenTree Faces Softer Rooms, Debt and NYSE Deadline

Updated Category News Views 34

A hotel operator can post positive earnings and still leave shareholders with a nasty headache, and GreenTree's third quarter is that kind of report. NYSE:GHG produced RMB243.0 million in revenue, down 22.2% from a year earlier, while net income slipped to RMB49.3 million from RMB59.0 million. This was not a one-line stumble. Room pricing, occupancy, franchise economics...

Continue Reading
Swim Readiness Depends on Skills, Not Birthdays Alone

Updated Category News Views 55

A child popping up calmly after a brief dunk tells you more than a birthday ever will. That is the sensible center of Woody Alpern's guidance for families weighing whether a child belongs in the next swim level. The Atlanta swim school expert's point is refreshingly free of the usual parental race: advancement is earned through repeatable skills, comfort, and judgment in...

Continue Reading
Travel Awards Spotlight Luxury Hospitality's Reach

Updated Category News Views 90

Hong Kong’s awards roll call reads less like a scorecard than a map of where premium travel wants its money and attention to go next. The 2026 World’s Travel & Hotel Awards, released November 20, cast a very wide net: heritage palaces, city hotels, beach retreats, airlines, cruise operators, tourism boards, restaurants, serviced apartments and a fair number of...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading

Top 5 Most Recently Viewed Articles

GoldHaven Resources Expands Exploration Amid Robust Gold Prices

Updated Category News Views 299

Gold's Resilience Fuels Growth Initiatives Gold prices have steadily stabilized above $4,200 per ounce, prompting renewed interest among investors seeking safe-haven assets. This robust price environment encourages extensive drilling programs aimed at expanding resource bases. GoldHaven Resources Corp. (CSE: GOH) is at the forefront of this momentum, actively advancing...

Continue Reading
HSBC Highlights Reliance Industries' Growth Potential and Strategy

Updated Category News Views 287

HSBC Upgrades Reliance Industries Stock Target Recently, HSBC raised its price target for Reliance Industries (RIL:IN) from INR 2,780.00 to INR 3,010.00 while maintaining a Hold rating. This revision reflects a promising outlook on the company's comprehensive business structure and financial standing. Core Sectors Driving Performance HSBC's analysts highlighted Reliance's...

Continue Reading
Vallourec's Strategic Move: Partial Redemption of Notes

Updated Category News Views 142

Vallourec's Strategic Financial Maneuver Vallourec, an industry leader in premium tubular solutions, has made a significant announcement regarding its senior notes due 2032. This decision is part of its ongoing strategy to enhance its financial stability and market position. Details of the Partial Redemption The company plans to redeem $82 million of its senior notes,...

Continue Reading
Health Assurance Foundation Teams Up to Enhance Healthcare Access

Updated Category News Views 80

The Health Assurance Foundation officially launched as a nonprofit back in 2024, focusing on strengthening the healthcare system by investing in local communities. Its mission? Making healthcare more equitable and accessible for everyone. Sounds good on paper, right? But when you peel back the layers, things get murky. Community Health Worker Initiative: Is It Enough? The...

Continue Reading
Market Pay Unveils Seamless POS Solution for Merchants Across Europe

Updated Category News Views 208

Market Pay Launches a Game-Changing Payment Solution The French fintech company Market Pay, a prominent player in the European payment processing field, is excited to unveil its new point-of-sale software payment solution. This innovative app integrates both terminal and smartphone payment options into a single, user-friendly platform. This development not only simplifies...

Continue Reading